Evidence map›Paper›PMID 37378767›Full record

ArticleAdvances in experimental medicine and biology2023

Proteomic Investigation of COVID-19 Severity During the Tsunamic Second Wave in Mumbai.

Sakshi Rajoria, Divya Nair, Kruthi Suvarna, Medha Gayathri J Pai, Akanksha Salkar, Viswanthram Palanivel, Ayushi Verma, Abhilash Barpanda, Gaurav Awasthi, Hastyn Doshi and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Sakshi Rajoria *Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Divya Nair *Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Kruthi Suvarna *Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Medha Gayathri J Pai *Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Akanksha SalkarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Viswanthram PalanivelDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Ayushi VermaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Abhilash BarpandaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Gaurav AwasthiDepartment of Chemical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Hastyn DoshiDepartment of Computer Science, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Vivek DharaDepartment of Mechanical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Ananya BurliDepartment of Chemical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Sachee AgrawalKasturba Hospital for Infectious Diseases, Chinchpokli, Mumbai, Maharashtra, India.
Om ShrivastavKasturba Hospital for Infectious Diseases, Chinchpokli, Mumbai, Maharashtra, India.
Jayanthi ShastriKasturba Hospital for Infectious Diseases, Chinchpokli, Mumbai, Maharashtra, India.
Sanjeeva SrivastavaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India. sanjeeva@iitb.ac.in.
Indian Institute of Technology Bombay · INKasturba Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maharashtra was severely affected during the noxious second wave of COVID-19, with the highest number of cases recorded across India. The emergence of new symptoms and dysregulation of multiple organs resulted in high disease severity during the second wave which led to increased difficulties in understanding the molecular mechanisms behind the disease pathology. Exploring the underlying factors can help to relieve the burden on the medical communities to some extent by prioritizing the patients and, at the same time, opening avenues for improved treatments. In the current study, we have performed a mass-spectrometry-based proteomic analysis to investigate the disease pathology using nasopharyngeal swab samples collected from the COVID-19 patients in the Mumbai region of Maharashtra over the period of March-June 2021, the peak of the second wave. A total of 59 patients, including 32 non-severe and 27 severe cases, were considered for this proteomic study. We identified 23 differentially regulated proteins in severe patients as a host response to infection. In addition to the previously identified innate mechanisms of neutrophil and platelet degranulation, this study revealed significant alterations of anti-microbial peptide pathways in severe conditions, illustrating its role in the severity of the infectious strain of COVID-19 during the second wave. Furthermore, myeloperoxidase, cathepsin G, and profilin-1 were identified as potential therapeutic targets of the FDA-approved drugs dabrafenib, ZINC4097343, and ritonavir. This study has enlightened the role of the anti-microbial peptide pathway associated with the second wave in India and proposed its importance in potential therapeutics for COVID-19.

Indexed as

COVID-19HumansIndiaProteomicsRitonavirSARS-CoV-2RitonavirCOVID-19Host responseMRMNasopharyngeal swabProteomicsSecond waveSeverity markers

Identifiers

PMID37378767
OpenAlexW4382344896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.